Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Daoud Al-Badriyeh, Siow Chin Heng, Chin Fen Neoh, Monica Slavin, Kay Stewart & David CM Kong. (2010) Pharmacoeconomics of voriconazole in the management of invasive fungal infections. Expert Review of Pharmacoeconomics & Outcomes Research 10:6, pages 623-636.
Read now
Read now
Carlos Rubio-Terrés & Santiago Grau. (2010) Pharmacoeconomics of voriconazole. Expert Opinion on Pharmacotherapy 11:6, pages 877-887.
Read now
Read now
. (2009) Supplement: Trends in invasive Candida infections and their treatment: focus on echinocandins. Current Medical Research and Opinion 25:7, pages 1729-1762.
Read now
Read now
Nigel O’Connor & Ann Borley. (2009) Prospective audit of the effectiveness of hydrocortisone premedication on drug delivery reactions following amphotericin B lipid complex. Current Medical Research and Opinion 25:3, pages 749-754.
Read now
Read now
Mario Cruciani & Giovanni Serpelloni. (2008) Management of Candida infections in the adult intensive care unit. Expert Opinion on Pharmacotherapy 9:2, pages 175-191.
Read now
Read now
Karen Moeremans & Lieven Annemans. (2006) Economic evaluation of the prevention and management of systemic fungal infections in neutropenic patients. Expert Opinion on Pharmacotherapy 7:14, pages 1931-1943.
Read now
Read now
Articles from other publishers (16)
Chin Fen Neoh, Esin Senol, Ates Kara, Ener Cagri Dinleyici, Stuart J. Turner & David C. M. Kong. (2018) Economic evaluation of micafungin versus liposomal amphotericin B (LAmB) for treating patients with candidaemia and invasive candidiasis (IC) in Turkey. European Journal of Clinical Microbiology & Infectious Diseases 37:9, pages 1777-1784.
Crossref
Crossref
C. F. Neoh, E. Senol, A. Kara, E. C. Dinleyici, S. J. Turner & D. C. M. Kong. (2017) Pharmacoeconomic evaluation of micafungin versus caspofungin as definitive therapy for candidaemia and invasive candidiasis (IC) in Turkey. European Journal of Clinical Microbiology & Infectious Diseases 37:3, pages 537-544.
Crossref
Crossref
Chin Fen Neoh, Esin Senol, Ates Kara, Ener Cagri Dinleyici, Stuart J. Turner & David C. M. Kong. (2017) Cost-effectiveness analysis of anidulafungin vs fluconazole for the treatment of invasive candidiasis (IC) in Turkey. Mycoses 60:11, pages 714-722.
Crossref
Crossref
Michael A. Pfaller & Mariana Castanheira. (2015) Nosocomial Candidiasis: Antifungal Stewardship and the Importance of Rapid Diagnosis. Medical Mycology, pages myv076.
Crossref
Crossref
Almudena Martín-Peña, Manuela Aguilar-Guisado & José Miguel Cisneros. (2014) Does the current treatment of invasive fungal infection need to be reviewed?. Enfermedades Infecciosas y Microbiología Clínica 32:8, pages 523-528.
Crossref
Crossref
Chin Fen Neoh, Monica Slavin, Sharon C.-A. Chen, Kay Stewart & David C.M. Kong. (2014) Echinocandins in the treatment of candidaemia and invasive candidiasis: clinical and economic perspectives. International Journal of Antimicrobial Agents 43:3, pages 207-214.
Crossref
Crossref
Chin Fen Neoh, Danny Liew, Monica A. Slavin, Debbie Marriott, Sharon C.-A. Chen, Orla Morrissey, Kay Stewart & David C. M. Kong. (2013) Economic evaluation of micafungin vs. Liposomal Amphotericin B (LAmB) for the treatment of candidaemia and Invasive Candidiasis (IC). Mycoses 56:5, pages 532-542.
Crossref
Crossref
C. F. Neoh, D. Liew, M. A Slavin, D. Marriott, S. C.-A. Chen, O. Morrissey, K. Stewart & D. C. M. Kong. (2013) Economic evaluation of micafungin versus caspofungin for the treatment of candidaemia and invasive candidiasis. Internal Medicine Journal 43:6, pages 668-677.
Crossref
Crossref
P. Zarb, B. Amadeo, A. Muller, N. Drapier, V. Vankerckhoven, P. Davey & H. Goossens. (2012) Antifungal therapy in European hospitals: data from the ESAC point-prevalence surveys 2008 and 2009. Clinical Microbiology and Infection 18:10, pages E389-E395.
Crossref
Crossref
Elizabeth Dodds Ashley. (2011) Pharmacoeconomics of antifungal therapy: current considerations. Current Opinion in Infectious Diseases 24, pages S30-S40.
Crossref
Crossref
C. F. Neoh, D. Liew, M. Slavin, D. Marriott, S. C.- A. Chen, O. Morrissey, K. Stewart & D. C. M. Kong. (2011) Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis. Journal of Antimicrobial Chemotherapy 66:8, pages 1906-1915.
Crossref
Crossref
W.J. Steinbach. (2010) Epidemiology of invasive fungal infections in neonates and children. Clinical Microbiology and Infection 16:9, pages 1321-1327.
Crossref
Crossref
Sarah M. Wieczorkiewicz, Jacqueline Jourjy & Larry Danziger. (2009) An update on the pharmacoeconomics of antifungal pharmacotherapy. Current Fungal Infection Reports 3:2, pages 103-110.
Crossref
Crossref
Curtis D. Collins, Jeffrey J. Ellis & Daniel R. Kaul. (2008) Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia. American Journal of Health-System Pharmacy 65:23, pages 2237-2243.
Crossref
Crossref
P. Pavese, Z. Ouachi, J.-P. Vittoz, B. Lebeau, L. Foroni, B. Allenet, J.-P. Stahl & P. François. (2007) Revue de pertinence des prescriptions des nouveaux antifongiques systémiques dans un hôpital universitaire. Médecine et Maladies Infectieuses 37, pages S223-S228.
Crossref
Crossref
F. Botterel. (2007) Démarche diagnostique et prise en charge des infections fongiques chez les patients immunodéprimés. Antibiotiques 9:1, pages 34-43.
Crossref
Crossref